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Abstract
Background: It is well known that lipids abnormally accumulate in the alveoli during idiopathic pulmonary
alveolar proteinosis (PAP). It is unclear, however, whether lipids also abnormally accumulate in serum. This study
investigated the serum lipid panels in idiopathic PAP patients and explored the relationships between serum levels
and the severity of idiopathic PAP.
Methods and Results: Clinical data including the level of serum lipids were evaluated in 33 non-diabetic
idiopathic PAP patients and 157 healthy volunteers. Serum levels of triglyceride were higher in PAP patients than
in healthy subjects (median: 192.00 mg/dl (P25: 104.36, P75: 219.00) vs 119.56 mg/dl (P25: 78.81, P75: 193.03), P <
0.05), while high-density lipoprotein cholesterol (HDL-C) levels were lower in patients than in the control group
(42.50 ± 10.30 vs 51.34 ± 12.06 mg/dl, P < 0.01). Forced expiratory volume in one second and forced vital capacity
in hypertriglyceridemia patients were lower than those in patients with normal triglyceride. Serum LDL-C and HDL-
C ratio correlated negatively with PaO2 (r = -0.403, P < 0.05) and positively with lactate dehydrogenase (r = 0.381,
P < 0.05).
Conclusions: PAP associates with high triglyceride and low HDL levels in the serum, and these lipids provide
potential intervention strategy for treatment.
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Introduction
Pulmonary alveolar proteinosis (PAP) is a rare lung dis-
ease in which the alveolar spaces are filled with lipopro-
teinaceous material [1,2]. PAP occurs in three clinically
distinct forms: congenital, secondary, and idiopathic
[1,3,4]. More than 90% of PAP patients are idiopathic
[2]. Most patients with PAP are symptomatic with pro-
gressive exertional dyspnea of insidious onset and
cough, and are hypoxemic in room air. A primary com-
plication of PAP is that it predisposes patients to pul-
monary infections. Disease outcomes vary from the
development of respiratory failure to full symptom reso-
lution. The primary treatment strategy for idiopathic
PAP is whole lung lavage.
Bronchoalveolar lavage fluid from PAP patients shows
a milky appearance compared with control samples and
contains large, foamy alveolar macrophages along with
an increased number of lymphocytes. The opacity is due
to an increased surfactant concentration, which has
been shown to accumulate due to reduced clearance
kinetics rather than increased synthesis rates. Surfactant,
a complex mixture of phospholipids and proteins, serves
to reduce surface tension within the lung. Cholesterol is
the most abundant neutral lipid of pulmonary surfac-
tant, constituting up to 90% of the neutral lipid materi-
als [1,5]. At least 80% of the cholesterol present in the
lung, and virtually all that in surfactant, is derived from
circulating lipoproteins, with very low-density lipopro-
tein believed to be the major vehicle of delivery to the
lung [6]. Because patients with PAP have increased lipo-
proteins in the lung, we hypothesized that circulating
lipoprotein levels would also be changed.
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serum lipids, lipoprotein levels, and PAP severity. The cur-
rent study investigated these relationships to determine
whether serum lipid levels would provide valuable clinical
information to assess and monitor disease progression.
Methods
Study design and population
The institutional review board committee of Peking
Union Medical College Hospital approved the protocol
of this study. Data from healthy volunteers were
obtained from persons who were examined in the Cen-
ter of Medical Examination in Peking Union Medical
College Hospital between April 2009 and May 2010. All
study participants provided informed consent. Data for
the PAP patients were obtained retrospectively from the
case records. Using a case-controlled study design, data
of 157 previously healthy persons were evaluated for the
level of lipids in a non-diabetic population and com-
pared to the idiopathic PAP cohort. There were 80 PAP
patients diagnosed in our hospital between January 2001
and February 2009. Complete datasets, including lipid
analysis and other criteria, were obtained from 33
patients at the time of diagnosis and were used in this
analysis. We included only idiopathic PAP patients with
normal fasting serum glucose levels (< 7.0 mmol/L) to
avoid potential confounding effects of diabetes mellitus
on serum lipid metabolism. The diagnosis of idiopathic
PAP was established by histopathologic examination of
material from open lung biopsies, transbronchial biop-
sies or bronchial alveolar lavage, and by exclusion of
secondary etiologies by history and laboratory investiga-
tion. Anti-GM-CSF antibodies were not measured in
this study because blood samples were not available dur-
ing the retrospective analysis. Patients were excluded if
they had a history of diabetes mellitus, chronic liver or
kidney disease, infection, cancer, or use of corticoster-
oids or lipid-lowing agents. Detailed demographic, medi-
cal history, history of smoking, body mass index (BMI),
blood pressure, fasting serum glucose, lipid levels (total
cholesterol (TC), triglyceride (TG), low-density lipopro-
tein cholesterol (LDL-C), high-density lipoprotein cho-
lesterol (HDL-C)), pulmonary function tests (including
forced expiratory volume in one second (FEV1), forced
vital capacity (FVC), FEV1/FVC, total lung capacity
(TLC) and carbon monoxide diffusion capacity (DLco),
arterial blood gas analysis in room air, and treatment
were all recorded and entered into a database.
Hypertriglyceridemia (hyper-TG) was defined as serum
TG ≥150 mg/dl. Hyper-low-density-lipoproteinemia
(hyper-LDL) was defined as serum LDL-C ≥130 mg/dl.
Hypercholesterolemia (hyper-TC) was defined as serum
TC ≥200 mg/dl. Hypo-high-density-lipoproteinemia
(hypo-HDL) was defined as serum HDL-C ≤40 mg/dl
based on the China’s guidelines of prevention and treat-
ment of adult dyslipidemia [7].
Assays
Laboratory examinations were performed on blood sam-
ples obtained after an overnight fasting. The levels of
serum TC, TG, HDL-C and LDL-C, fasting serum glucose,
and lactate dehydrogenase (LDH) were measured with
commercial kits using an automated chemistry analyzer
(Olympus AU5400, Japan). All arterial blood samples were
collected with the patient breathing room air and were
used to calculate alveolar-arterial oxygen pressure differ-
ence (P(A-a)O2) (Radiometer ABL835, Denmark).
Pulmonary function tests were performed with the Master
Screen Body equipment (Jaeger, Germany) using current
recommendations of the ATS/ERS Task Force on standar-
dizations of pulmonary function tests [8-10]. The values
were expressed as a percentage of the predicted values for
gender, age and height. Data of DLco was normalized to
hemoglobin levels.
Statistical analysis
Statistics were performed with SPSS version 11.0.
Normality of variables was tested by the Kolmogorov-
Smirnov test. An unpaired, two tailed t-test and a Chi-
squared analysis was used for comparison between the
two groups. The nonparametric Mann-Whitney U-test
was used when data were not normally distributed. Spe-
cifically, TG data in this group and also in the general
population was not normally distributed and was evalu-
ated by the nonparametric test. A p-value of <0.05 was
considered statistically significant.
Results
I nt h eP A Pg r o u p ,t h e r ew e r e2 3m e na n d1 0w o m e n
with a mean age of 43.9 years old. Seven subjects had a
history of cardiovascular disease, cerebral vascular dis-
ease, or hypertension, while fifteen subjects had a his-
tory of smoking, and six patients had previously
accepted sole or whole lung lavage therapy.
The patient characteristics of the PAP group were
compared with those of the healthy control group, as
shown in Table 1. There were no significant differences
in age, BMI, and gender between the two groups (p =
not significant (NS)). Furthermore, no significant differ-
ence was found in the smoking status, cardiovascular
disease, cerebral vascular disease, or hypertension (p =
NS). The mean systolic blood pressure (SBP), diastolic
blood pressure (DBP), and fasting serum glucose levels
were all within normal ranges, and there was no signifi-
cant difference between the two groups (p = NS).
Serum levels of TG (median: 192.00 mg/dl (P25:
104.36, P75: 219.00) vs 118.65 mg/dl (P25:7 8 . 8 1 ,P75:
193.03), p = 0.011) and LDL-C (133.41 ± 35.54 vs
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in PAP patients than healthy subjects, while HDL-C
levels were lower in patients than those in controls
(42.56 ± 10.30 mg/dl vs 51.34 ± 12.06 mg/dl, p < 0.001).
In patients and healthy subjects, the TC/HDL-C ratios
were 4.89 ± 1.41 and 3.90 ± 1.05, respectively (p <
0.001), LDL-C/HDL-C ratios were 3.30 ± 1.17 and 2.46
±0 . 8 7( p < 0.001), and TG/HDL-C ratios were 4.75 ±
3.11 and 3.28 ± 2.88 (p = 0.001). However, the levels of
TC were similar in the two groups (p = NS).
Lipid metabolism is influenced by many factors, thus,
we compared the effects of PAP, gender, age, BMI,
patient history, smoking, and blood glucose on triglycer-
ide and HDL-C levels by logistic regression. Only PAP
and BMI were significantly associated with triglyceride
and HDL-C levels. PAP did not have effects on LDL-C
and TC levels in this analysis.
According to the definitions of hyper-TG, hyper-LDL,
hyper-TC, and hypo-HDL, patients were divided into
hyper-, hypo-, or normal groups. We found that PAP
patients were more likely to be in the hyper-TG group
compared to the healthy control group (OR = 2.32, 95%
CI 1.08-4.97, p = 0.028). PAP patients were also more
likely to be in the hypo-HDL group compared to those
in the control group (OR = 5.40, 95% CI 2.37-12.32,
pä0.001). The hyper-TC and hyper-LDL comparisons
did not show any differences between PAP patients and
the control group (OR = 1.46, 95% CI 0.69-3.12, p=N S ;
OR = 2.04, 95% CI 0.95-4.40, p = NS, respectively).
To identify relationships between abnormal lipid levels
and PAP severity, we compared the partial pressure of
arterial oxygen (PaO2), LDH, and pulmonary function
tests of the hyper-TG PAP group and the normal TG
PAP group. We found that in the hyper-TG PAP group,
FEV1 and FVC were lower than those of the normal TG
PAP group (p < 0.05 for both). TLC and DLco were not
significantly different between the two groups (Table 2).
Correlations between serum LDL-C/HDL-C ratios and
PaO2 or LDH levels are shown in Figure 1. Serum LDL-
C/HDL-C ratios correlated negatively with PaO2 levels
(r = -0.403, p = 0.027) and positively with LDH (r =
0.381, p = 0.034). Serum LDL-C/HDL-C ratios did not
correlate with P(A-a)O2 levels (r = 0.335, p =0 . 0 7 0 ) .
Moreover, there was no linear correlation between
serum lipids and FEV1 or FVC.
Discussion
Multiple studies have focused on lipid metabolism disor-
ders in coronary vascular disease, diabetes mellitus, obe-
sity, and atherosclerosis. A growing body of literature
suggests that metabolic syndromes could also be present
in patients with a variety of pulmonary diseases, includ-
ing pulmonary arterial hypertension [11] and lung fibro-
sis [12]. PAP, also referred to as alveolar lipoproteinosis,
is an enigmatic disorder characterized by abnormal
intra-alveolar surfactant accumulation. Elevated serum
cholesterol levels have been reported in 19% of PAP
patients, however, sample size and characteristics were
Table 1 Characteristics of the patients and healthy subjects
Control
(n = 157)
Patients
(n = 33)
P
Sex (male/female) 84/73 23/10 0.088
Mean age (yrs) 41 ± 12 44 ± 9 0.195
BMI (kg/m
2) 24.6 ± 3.6 23.7 ± 3.7 0.223
Cardiovascular history 19/144 (13.2%) 7/33 (21.2%) 0.368
Smoking status:yes/total (%) 48/144 (33.3%) 15/33 (45.5%) 0.19
Systolic blood pressure (mmHg) 122 ± 14 121 ± 18 0.817
Diastolic blood pressure (mmHg) 78 ± 10 79 ± 13 0.727
Fasting serum glucose (mmol/l) 4.67 ± 0.44 4.66 ± 0.64 0.936
TC (mg/dl) 191.24 ± 35.60 198.87 ± 43.16 0.283
TG (mg/dl)* 118.65(78.81-193.03) 192.00(104.36-219.00) 0.011
HDL-C (mg/dl) 51.34 ± 12.06 42.56 ± 10.30 <0.001
LDL-C (mg/dl) 119.56 ± 32.04 133.41 ± 35.54 0.03
LDL/HDL 2.46 ± 0.87 3.30 ± 1.17 <0.001
TG/HDL 3.28 ± 2.88 4.75 ± 3.11 0.001
TC/HDL 3.90 ± 1.05 4.89 ± 1.41 <0.001
Hb (g/L) 145.28 ± 15.01 158.85 ± 22.66 <0.001
FEV1 pred (%) 93.74 ± 13.33 76.79 ± 19.28 <0.001
FVC pred (%) 96.80 ± 12.37 75.98 ± 19.97 <0.001
FEV1/FVC (%) 83.12 ± 6.74 83.54 ± 6.53 0.757
Values are expressed as the mean ± SD unless otherwise indicated. *: Values are expressed as median, 25% and 75%. Nonparametric Mann-Whitney U-test was
used, as data were not normally distributed.
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were significantly increased in the serum of PAP
patients compared with those of controls [13]. More-
over, Inoue et al. showed that hyperlipemia occurs in
4.2% of Japanese idiopathic PAP patients [14], but
detailed lipid profiles were not described. This led us to
hypothesize that serum lipoproteins could also be ele-
vated in PAP patients.
Our data shows that serum lipid level differences did
associate with PAP, as TG levels are higher and HDL-C
levels are lower in PAP patients compared to those in
the normal control group. PAP patients with hyper-TG
had lower FEV1 and FVC than PAP patients with nor-
mal TG levels. In our study, the mean BMI in the PAP
group was below 25 kg·m
-2, which is within the normal
weight range. We also excluded patients with diabetes
or patients using corticosteroids or lipid-regulating
drugs. Blood pressure is also matched between the two
groups. Therefore, we can conclude that the hyperlipe-
mia associated with PAP is likely an independent factor.
Of interest, total triglyceride, but not total cholesterol,
in our PAP group is elevated.
Although the etiology of PAP remains unclear, recent
studies into PAP pathogenesis have revealed the impor-
tant roles for GM-CSF [2,5,15]. Alveolar macrophages
from GM-CSF gene knockout mice have reduced capa-
city for surfactant catabolism [2,16]. Studies have shown
that exogenous administration of GM-CSF benefits
some PAP patients, which supports the potential of
GM-CSF as a replacement therapy for PAP [17-19].
The mechanisms of dyslipoproteinemia in PAP are
unknown, but may occur through GM-CSF roles. GM-
CSF can lower plasma cholesterol and plasma triglycer-
ides levels, elevate expression of very-low density lipo-
protein receptors, decrease scavenger receptor
expression on human macrophages, and attenuate the
accumulation of cholesterol esters [20]. GM-CSF is also
a pro-inflammatory cytokine, and recent evidence sug-
gests that chronic inflammatory diseases associate with
metabolic syndrome and insulin resistance [21,22]. GM-
CSF increases tumor necrosis factor-a and interleukin-
1b gene expression, which could affect lipid metabolic
disorders [21,23,24].
Table 2 Comparison of clinical features between hyper-
TG and normal TG PAP patients
Normal TG
patients
(N = 14)
Hyper-TG
patients
(N = 19)
P
Sex (male/female) 11/3 12/7 0.455
Age (yrs) 43.79 ± 8.26 43.89 ± 8.91 0.971
BMI (kg/m
2) 24.4 ± 5.00 23.20 ± 2.55 0.417
Hypertension history (yes/
no)
2/12 5/14 0.67
Smoking history (yes/no) 8/6 7/12 0.304
Systolic blood pressure
(mmHg)
119 ± 16 123 ± 19 0.547
Diastolic blood pressure
(mmHg)
77 ± 13 80 ± 14 0.606
Fasting serum glucose
(mmol/l)
4.83 ± 0.77 4.54 ± 0.50 0.21
Hb (g/L) 152.07 ± 22.11 163.84 ± 22.30 0.143
LDH (U/l) 295.85 ± 118.42 257.16 ± 91.10 0.305
PaO2 65.42 ± 22.08 66.18 ± 12.34 0.912
PA-aO2 (mmHg) 40.00 ± 21.55 39.20 ± 12.67 0.897
FEV1 pred (%) 87.73 ± 15.70 70.71 ± 18.71 0.022
FVC pred (%) 87.32 ± 16.44 69.67 ± 19.31 0.022
FEV1% 82.70 ± 5.8 84.01 ± 7.00 0.620
TLC pred (%) 79.89 ± 10.99 75.43 ± 12.83 0.373
DLco pred (%) 67.80 ± 13.80 60.15 ± 16.17 0.255
Values are expressed as the mean ± SD.
Figure 1 Correlations between serum LDL/HDL ratio and PaO2 (A) or LDH (B). Serum LDL-C/HDL-C ratios correlated negatively with PaO2
levels (r = -0.403, p = 0.027) and positively with LDH (r = 0.381, p = 0.034), n = 33.
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tor-g (PPAR-g) mRNA and protein are highly expressed
in alveolar macrophages in normal subjects [25,26]. In
PAP patients, both PPAR-g mRNA and the PPAR-g-
regulated lipid scavenger receptor CD36 in alveolar
macrophages are reduced. In PAP patients, GM-CSF
treatment increased PPAR-g to control levels [25,27]. In
addition to serving as a potential factor in GM-CSF reg-
ulation of lung homeostasis, PPAR-g is also an impor-
tant transcriptional regulator of genes involved in
glucose and lipid metabolism [28]. Restoration of PPAR-
g reduced lipid accumulation in alveolar macrophages of
GM-CSF knockout mice [26]. PPAR-g agonists are com-
monly used in the treatment of diabetes, and have
effects in lowering plasma TG and LDL-C levels, and
increasing HDL-C levels [29,30]. Hence, PPAR-g may
partially be involved in lipid metabolism in PAP.
We found that hyper-TG correlated with lower FEV1
and FVC. Serum LDL-C/HDL-C ratios correlated nega-
tively with PaO2 levels and positively with LDH. Pre-
vious studies have demonstrated a correlation between
LDH and PaO2 [1,31]. In our study, TG levels did not
correlate with LDH levels, which is a major biomarker
currently available for PAP severity. Therefore, whether
the severity of PAP is related to the degree of dyslipo-
proteinemia remains to be clarified.
From this study, we recommend that serum lipid analy-
sis be included in the evaluation of PAP patients. The
possibility that PAP patients may be at a higher risk for
coronary heart disease should also be evaluated. Further-
more, our study suggests that lipid-modifying drugs may
be a potential novel intervention for PAP patients.
While the present findings are interesting, our study
has several limitations. The majority of our patients
were not re-evaluated for lipid levels when they were
followed up at the outpatient clinics. Therefore, we
could not ascertain whether lipid levels are higher in
patients during active disease compared to remission. A
prospective and comprehensive study to validate the
role of circulating lipids would be required. A prospec-
tive study design would also allow anti-GM-CSF antibo-
dies to be measured, to clarify the idiopathic auto-
immune PAP from secondary PAP and to determine the
relationship of titration of anti-GM-CSF and lipid
abnormalities. Hypertriglyceridemia and hypo-high-den-
sity-lipoproteinemia are more prevalent in non-diabetic
idiopathic PAP patients than in healthy controls. While
the etiology of PAP is likely to be multifactorial, further
studies are warranted to determine the potential benefits
of lipid monitoring and intervention for PAP patients.
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